Free shipping for orders over 280 CHF / 270 €
Regenerative treatment of initial carious lesions
– Professional product, sold to dental professionals only –
CURODONTTM REPAIR arrests and reverses initial carious lesions through enamel regeneration.
Its Monomer-Peptide 104 patented technology remineralises the enamel structure until the depth of the defect, preserving the tooth.
Non-invasive, easy-to-use, and pain-free. Suitable for all patients
Box contains 10 units of ready-to-use applicators.
One applicator can treat 1-3 lesions per patient.
USE
In office only
€ 270.00 excl. VAT
For orders from Germany, visit minilu.de
For orders from Switzerland, visit kaladent.ch
Guided Enamel Regeneration (GER) is a regenerative treatment of initial carious lesions. GER bridges the gap between prevention and invasive restorative treatments. It enables effective therapy of initial caries through in-depth regeneration of the enamel, whilst still maintaining the integrity of the tooth. By diffusing rapidly until the depth of early, active, non-cavitated early carious lesions (Caries classification table for indications of CurodontTM Repair) and forming new hydroxyapatite crystals, the Monomer-Peptide 104 technology in CurodontTM Repair enables Guided Enamel Regeneration via an easy, non-invasive and pain-free application.
Carious lesion with a pseudo-intact enamel surface layer
CURODONT REPAIR Application
Smooth Surface
CURODONT REPAIR Application
Interproximal Surface
CURODONT REPAIR Application
Occlusal Surface
CURODONT REPAIR Application
Ortho Case
Guided Enamel Regeneration (GER) is essentially a tissue regeneration treatment concept wherein tooth enamel is rebuilt after being lost to caries and wear, without the need to drill the tooth.
CurodontTM Repair is a low-viscosity liquid material that carries the globally patented ‘Monomer-Peptide 104‘ technology in the highest concentration. This revolutionary technology employs a short, ‘intelligent’ peptide, made of naturally occurring amino acids, to promote deposition of hydroxyapatite (the main tooth-building mineral) within carious lesions and stop the progression of incipient lesions
CurodontTM Repair employs the clinically proven and award-winning ‘Monomer-Peptide 104‘ technology to bring about guided enamel regeneration within early, non-cavitated enamel lesions. When applied, this technology penetrates until the very depth of the carious lesion. Once inside and triggered by the acidic environment of carious lesions, the intelligent peptide monomers assemble to form a matrix, which resembles the natural enamel matrix. This matrix then attracts calcium and phosphate ions from the saliva and promotes the formation and deposition of new hydroxyapatite crystals, essentially reversing the mineral loss seen as a result of caries.
Caries is a slowly progressing dental disease. In its advanced stages, when it has progressed to the middle or inner thirds of dentin, the carious lesions may get cavitated. Once a cavity develops, the only resort is to restore with an artificial plastic material. Drilling and filling of carious lesions is the beginning of the death spiral of a tooth, which eventually ends with tooth loss. Therefore, intervening when the carious lesion is still in its incipient stages avoids or delays the need for restorations and elongates the life of a tooth. Curodont Repair helps regenerate the ‘lost’ enamel and gives teeth a fresh start.
No. CurodontTM Repair can be used in conjunction with other remineralising agents, such as fluoride varnish, to optimize enamel regeneration and mineralization. In fact, the concurrent use of CurodontTM Repair and fluoride varnish has been successfully used to produce greater inactivation of caries compared to fluoride varnish alone.*
However, all treatments should be carried out only after an interval of at least 5 minutes after the application of CurodontTM Repair and not before.
*Alkilzy M, Tarabaih A, Santamaria RM, Splieth CH. Self-assembling Peptide P11-4 and Fluoride for Regenerating Enamel. J Dent Res. 2018 Feb;97(2):148-154.
Doberdoli D et al. Randomized Clinical Trial investigating Self-Assembling Peptide P11-4 for Treatment of Early Occlusal Caries. Sci Rep 2020;10:4195.
€ 270.00 excl. VAT
€ 270.00 excl. VAT